[Teva] they may only accuse NVS with stealing some Copaxone trade secrets - not all of them.
This would obviously help vis-à-vis the Copaxone CP, but it might hurt the chances for Teva to prevail in the lawsuit and it would likely reduce the monetary damages if they did prevail.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”